These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 1709854)

  • 21. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Osteolytic metastases of breast cancer and biphosphonates].
    Lortholary A; Alleaume C; Pein F; Larra F
    Rev Med Interne; 1992; 13(3):238-42. PubMed ID: 1410908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trials with bisphosphonates.
    Lombardi A; Santora AC
    Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tiludronate. A new treatment for an old ailment: Paget's disease of bone.
    Morales-Piga A
    Expert Opin Pharmacother; 1999 Nov; 1(1):157-70. PubMed ID: 11249559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
    Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
    Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR
    J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of bisphosphonates].
    Nakatsuka K
    Nihon Rinsho; 2003 Feb; 61(2):219-25. PubMed ID: 12638211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
    Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
    J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paget's disease with osteolytic lesions: combining medical and surgical treatments.
    Brumsen C; Bloem RM; Papapoulos SE
    Neth J Med; 1992 Jun; 40(5-6):292-8. PubMed ID: 1436268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
    Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
    J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralisation defects with pamidronate therapy for Paget's disease.
    Adamson BB; Gallacher SJ; Byars J; Ralston SH; Boyle IT; Boyce BF
    Lancet; 1993 Dec; 342(8885):1459-60. PubMed ID: 7902484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modern therapy for Paget's disease of bone: focus on bisphosphonates.
    Devogelaer JP
    Treat Endocrinol; 2002; 1(4):241-57. PubMed ID: 15799218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates in the treatment of metabolic bone diseases.
    Rodan GA; Balena R
    Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium.
    Stewart GO; Gutteridge DH; Price RI; Ward L; Retallack RW; Prince RL; Stuckey BG; Kent GN; Bhagat CI; Dhaliwal SS
    Bone; 1999 Feb; 24(2):139-44. PubMed ID: 9951784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.